CurrentEndo — Reproductive endocrinology

Structured nutritional management of insulin resistance in women with PMOS (formerly PCOS) receiving GLP-1RA therapy

2026-11-14T06:45:51.583Z

Research article · Diabetes Res Clin Pract, 2026.

Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025

2026-11-13T15:47:59.646Z

Cohort study · Clin Endocrinol (Oxf), 2026.

Study of Visceral Adiposity Index and Free Androgen Index in Indian Women With PCOS: A Cross‐Sectional Study

2026-11-13T15:47:59.646Z

Cross-sectional study · Clin Endocrinol (Oxf), 2026.

Landscape of pathogenic mutations in premature ovarian insufficiency

2026-11-13T11:02:00.546Z

Case-control study · Nat Med, 2023. Pathogenic/likely pathogenic variants in known POI-causative genes: POI 193 (18.7%)

Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial

2026-11-13T11:00:06.281Z

Randomized controlled trial · JAMA Netw Open, 2023. FSFI improvement (baseline to 6 months): CLT mean 5.2 ± 1.5 points · SLT mean 7.9 ± 1.2 points

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

2026-11-13T10:58:58.035Z

Randomized controlled trial · Lancet, 2023. Change in VMS frequency and severity vs placebo, weeks 4 and 12 — Fezolinetant 30 mg vs Placebo: difference in change in least squares mean -1.87; p<0.001; VMS frequency, week 4; SE 0.42

Psychosocial Functioning in Transgender Youth after 2 Years of Hormones

2026-11-13T10:58:35.797Z

Cohort study · N Engl J Med, 2023. Psychosocial functioning, 2 years: Appearance congruence, positive affect and life satisfaction increased

Menopause‐Related Changes in Body Composition Are Associated With Subsequent Bone Mineral Density and Fractures: Study of Women's Health Across the Nation

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Each SD (6.9%) increment in lean mass loss: lower FN BMD, p < 0.0001 0.010 g/cm2

Longitudinal patterns of abdominal visceral and subcutaneous adipose tissue, total body composition, and anthropometric measures in postmenopausal women: Results from the Women’s Health Initiative

2026-11-13T10:51:50.896Z

Cohort study · Int J Obes (Lond), 2023. 6 years: Important differences in VAT and SAT by age and race/ethnicity

Effect of sleep restriction on insulin sensitivity and energy metabolism in postmenopausal women: A randomized crossover trial

2026-11-13T10:47:54.884Z

Randomized controlled trial · Obesity (Silver Spring), 2023. Low-dose insulin GIR: HS 2.55 ± 0.22 mg/kg/min · SR 2.03 ± 0.20 mg/kg/min

Polycystic ovary syndrome is associated with weight‐loss attempts and perception of overweight independent of BMI: a population‐based cohort study

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Weight-loss attempts, age 31 years: PCOS 47% · Control 34%

Young-onset diabetes in women with Polycystic Ovary Syndrome: A territory-wide retrospective analysis in Hong Kong

2026-11-13T10:35:20.262Z

Cohort study · Diabetes Res Clin Pract, 2023. Incident diabetes, mean follow-up 6.28 ± 4.20 (PCOS) and 6.95 ± 4.33 (controls) years: PCOS 14.25/1000 person-years · Controls 3.45

Association between triglyceride-glucose index and risk of cardiovascular disease among postmenopausal women

2026-11-13T10:28:29.610Z

Cohort study · Cardiovasc Diabetol, 2023. Incident CVD, median follow-up 12 years — Q4 vs Q1: HR 1.70 (95% CI 1.21-2.38); adjusted for potential confounders

Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity

2026-11-13T10:20:05.638Z

Randomized controlled trial · Diabetes Obes Metab, 2023. Gastric retention of solid meal, 4 hours after ingestion: Semaglutide 37%

Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions

2026-11-13T10:10:38.237Z

Secondary analysis · Horm Res Paediatr, 2023. Morning thyroid-stimulating hormone (TSH) — PCOS vs Controls; p < 0.01; mean TSH higher in PCOS

A National Survey of United States-Based Endocrinologists Who Prescribe Gender-Affirming Hormone Therapy

2026-11-13T10:04:31.875Z

Cross-sectional study · Endocr Pract, 2023. Practice requires documented psychosocial evaluation from a mental health professional before initiating GAHT: Respondents whose practice required documentation of a psychosocial evaluation before initiating GAHT 42.9%

Comparison of the Subcutaneous and Intramuscular Estradiol Regimens as Part of Gender-Affirming Hormone Therapy

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Weekly E2 dose: SC 3.75 (IQR 3-4 mg) mg · IM 4 (IQR 3-5.15 mg) mg

Incidence and Factors Associated With Acne in Transgender Adolescents on Testosterone: A Retrospective Cohort Study

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Incidence of acne after testosterone initiation: No baseline acne 46 (77%)

Phenotype Prevalence and Health-Related Quality of Life of Lebanese Women With Polycystic Ovary Syndrome

2026-11-13T10:04:31.875Z

Cross-sectional study · Endocr Pract, 2022. Phenotype A (most common phenotype) 67%

The Effect of Gender-Affirming Hormone Therapy on the Risk of Subclinical Atherosclerosis in the Transgender Population: A Systematic Review

2026-11-13T10:04:31.875Z

Meta-analysis · Endocr Pract, 2023. Markers of subclinical atherosclerosis: Trans men receiving GAHT: increased carotid thickness, brachial-ankle pulse wave velocity, and decreased vasodilation

17β‐hydroxysteroid dehydrogenase type 2 activity, expression and cellular localization in abdominal adipose tissues from women

2026-11-13T09:59:57.591Z

Mechanistic study · Clin Endocrinol (Oxf), 2022. Rate of 14 C-E1 formation from 14 C-E2 — OM vs SC; p < .0001; significantly higher in OM

Assessing the androgenic and metabolic heterogeneity in polycystic ovary syndrome using cluster analysis

2026-11-13T09:59:57.591Z

Research article · Clin Endocrinol (Oxf), 2022. Hormone levels in smaller vs larger cluster (discovery cohort) — Smaller cluster vs Larger cluster: LH; p < .001; significantly higher with smaller cluster

Association between serum β‐oestradiol and health‐related quality of life in postmenopausal women with degenerative lumbar scoliosis

2026-11-13T09:59:57.591Z

Case-control study · Clin Endocrinol (Oxf), 2022. lumbar spinal bone mineral density (LSBMD) and serum E2 significantly reduced in DLS vs control

Breast satisfaction in adult women with Turner syndrome—An international survey employing the BREAST‐Q questionnaire

2026-11-13T09:59:57.591Z

Cross-sectional study · Clin Endocrinol (Oxf), 2022. BREAST-Q scores — TS vs Army of Women; p = .021; 'Satisfaction with Breast': significantly lower in TS

Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Nine coagulation pathway proteins: Seven pro-coagulation proteins (plasminogen activator inhibitor-1, fibrinogen, fibrinogen gamma chain, fibronectin, d-dimer, P-selectin, plasma kallikrein) did not differ between PCOS and controls

Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review

2026-11-13T09:59:57.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2023. Cycle regularity: COCP 100% · No medical treatment 0%

Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. VAT area, 12 months — AI vs Controls: mean adjusted difference -5.00 cm2 (CI -16.9, 6.91); p = .55; no statistically significant difference

Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis

2026-11-13T09:59:57.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2023. Carnitine vs Placebo: RR 3.42 (95% CI 2.39 to 4.89); ovulation; I2 = 0%

Endogenous testosterone concentrations and muscle mass, strength and performance in women, a systematic review of observational studies

2026-11-13T09:59:57.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2023. Association of testosterone with muscle mass, strength and performance: No association between total testosterone and muscle mass, strength or performance

Luteinizing hormone β‐subunit deficiency: Report of a novel LHB likely pathogenic variant and a systematic review of the published literature

2026-11-13T09:59:57.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2022. Index case age at presentation (infertility) 36 years

Role of kisspeptin in polycystic ovarian syndrome: A metabolomics study

2026-11-13T09:59:57.591Z

Case-control study · Clin Endocrinol (Oxf), 2023. Serum kisspeptin — PCOS vs Controls; p = 0.011; significantly elevated in PCOS

Self‐reported sleep quality and exercise in polycystic ovary syndrome: A secondary analysis of a pilot randomized controlled trial

2026-11-13T09:59:57.591Z

Secondary analysis · Clin Endocrinol (Oxf), 2023. Poor sleep quality (PSQI >5), baseline: Proportion with poor sleep quality 79%

The association between sex hormones and the change in brain‐predicted age difference in older women

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Brain-PAD: Higher baseline brain-PAD (older brain age) in highest vs lowest DHEA tertile, unadjusted analysis p = .04

The effect of hormone replacement therapy on cognition and mood

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Heterogeneous results; firm conclusions challenging

The TGFβ system and TIMP1 and 3 genotypes in Turner syndrome—Relation with aortic congenital malformations

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. TGFβ, MMPs, TIMPs and genotype in relation to TS, cardiovascular risk and congenital heart disease: TS participants had lower TGFβ1 and TGFβ2 values vs controls

Classic and 11-oxygenated androgens in serum and saliva across adulthood: a cross-sectional study analyzing the impact of age, body mass index, and diurnal and menstrual cycle variation

2026-11-13T09:58:18.729Z

Cross-sectional study · Eur J Endocrinol, 2023. Serum androgens vs age-adjusted BMI (%change per kg/m2): 5α-dihydrotestosterone %change per kg/m2, men -5.54% (95% CI -8.10 to -2.98)

Family building after diagnosis of premature ovarian insufficiency: a cross-sectional survey in 324 women

2026-11-13T09:58:18.729Z

Cross-sectional study · Eur J Endocrinol, 2023. Children after POI diagnosis among women who wanted to build a family: Had children after diagnosis (of women who wanted a family) 41%

Persistence of foetal testicular features in patients with defective androgen signalling

2026-11-13T09:58:18.729Z

Mechanistic study · Eur J Endocrinol, 2023. All patients' gonadal tissues show exclusive expression of HSD17B3 in Sertoli cells (SCs)

Serum testosterone and sex hormone–binding globulin are inversely associated with leucocyte telomere length in men: a cross-sectional analysis of the UK Biobank study

2026-11-13T09:58:18.729Z

Cross-sectional study · Eur J Endocrinol, 2023. Standardised LTL by total testosterone (adjusted for sociodemographic, lifestyle and medical factors) — Q1 vs Q5: difference in standardised LTL 0.09 (95% CI 0.08-0.10); P < .001; longer LTL with Q1; total testosterone inversely associated with LTL

Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Change in total testosterone (TT), calculated free testosterone (cFT) and A4 after GAHT initiation, 3 months: Mean TT decrease 18.4 nmol/L (95% CI, -19.4 to -17.4, P < 0.001; -97.1%)

Just as Tall on Testosterone; a Neutral to Positive Effect on Adult Height of GnRHa and Testosterone in Trans Boys

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Adult height (BA ≤14 years at start): BA ≤14 years at start 172.0 ± 6.9 cm

Regional Variation in Hormonal and Metabolic Parameters of White and Black Women With PCOS in the United States

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Hormonal and metabolic parameters, Alabama vs California, adjusted for age and body mass index (BMI) — Alabama vs California: aOR 1.8 (95% CI 1.4-2.4); P < 0.001; Hirsutism; more likely in Alabama

Reproductive Phenotypes and Genotypes in Men With IHH

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Partial puberty as predictor of pulsatile LH secretion — Partial puberty vs Absent puberty: OR 10.8 (95% CI 3.6-38.6); P < .001; logistic regression, R2 = 0.71

Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency

2026-11-13T05:31:06.457Z

Research article · Nat Med, 2023. Penetrance of heterozygous variants in reported POI genes: Limited evidence for any previously reported autosomal dominant effect

Menopausal hormone therapy and dementia: nationwide, nested case-control study

2026-11-13T05:28:29.082Z

Case-control study · BMJ, 2023. All cause dementia — Oestrogen-progestogen therapy vs Never used: HR 1.24 (95% CI 1.17 to 1.33)

Standards of Care for Transgender and Gender Diverse People

2026-11-13T05:28:04.168Z

Guideline or statement · JAMA, 2023.

Hormone Replacement Therapy after Pubertal Induction in Adolescents and Young Adults with Turner Syndrome: A Survey Study

2026-11-13T04:57:29.624Z

Cross-sectional study · Horm Res Paediatr, 2023. HRT practice patterns — Pediatric gynecology vs Pediatric endocrinology; Gynecologists 4 times less likely to prefer hormonal contraceptives and 4 times more likely to favor transdermal estradiol 100 μg/day vs lower doses

A Model Combining Testosterone, Androstenedione and Free Testosterone Index Improved the Diagnostic Efficiency of Polycystic Ovary Syndrome

2026-11-13T04:53:22.663Z

Diagnostic or prognostic study · Endocr Pract, 2023. Diagnostic performance of Andro for PCOS: Andro: Youden index 0.65; sensitivity 81.82%; specificity 83.16%

Association of Insulin-Like Growth Factor-1 With Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis

2026-11-13T04:53:22.663Z

Meta-analysis · Endocr Pract, 2022. Serum IGF-1 levels — PCOS vs Controls: SMD 0.89 (95% CI 0.34-1.45); P = .002; higher with PCOS

Risk Assessment and Coronary Artery Calcium Scoring in Transgender and Gender-Diverse Individuals Receiving Gender-Affirming Hormone Therapy

2026-11-13T04:53:22.663Z

Cross-sectional study · Endocr Pract, 2022. CAC score >0 to 99: Transwomen 2 (8.3%) · Transmen 26 (12.5%)